Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib by Tannenbaum, Hyman et al.
doi:10.1136/ard.2003.015974 
 2004;63;1419-1426; originally published online 27 Feb 2004; Ann Rheum Dis
  
Bliddal, D Uebelhart, S Adami, F Navarro, A Lee, A Moore and A Gimona 
H Tannenbaum, F Berenbaum, J-Y Reginster, J Zacher, J Robinson, G Poor, H
  
 double blind study versus placebo and celecoxib
osteoarthritis of the knee: a 13 week, randomised, 
Lumiracoxib is effective in the treatment of
 http://ard.bmj.com/cgi/content/full/63/11/1419




4 online articles that cite this article can be accessed at: 
  
 http://ard.bmj.com/cgi/content/full/63/11/1419#BIBL
This article cites 29 articles, 9 of which can be accessed free at: 
Rapid responses
 http://ard.bmj.com/cgi/eletter-submit/63/11/1419
You can respond to this article at: 
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
Topic collections
 (753 articles) Osteoarthritis 
 (4550 articles) Musculoskeletal syndromes 
 (3120 articles) Drugs: musculoskeletal and joint diseases 
 (2984 articles) Degenerative joint disease 
 (688 articles) Biological agents 
 (5440 articles) Pain (neurology) 
  
Articles on similar topics can be found in the following collections 
 Notes   
 http://journals.bmj.com/cgi/reprintform
To order reprints of this article go to: 
 http://journals.bmj.com/subscriptions/
 go to: Annals of the Rheumatic DiseasesTo subscribe to 
 on 14 July 2009 ard.bmj.comDownloaded from 
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Objectives: To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for
osteoarthritis (OA) in a 13 week, multicentre, randomised, double blind study.
Methods: After a 327 day washout period for non-steroidal anti-inflammatory drugs, 1702 patients with
knee OA were randomised to lumiracoxib 200 or 400 mg once daily (od), celecoxib 200 mg od, or
placebo (2:2:2:1). A visual analogue scale (VAS) pain intensity >40 mm was required. Primary efficacy
variables were OA pain intensity (VAS mm) in the target knee, patient’s global assessment of disease
activity (VAS mm), and WOMAC pain subscale and total scores at 13 weeks. OA pain intensity, patient’s
and physician’s global assessment of disease activity, and WOMAC (total and all subscale scores) were
analysed by visit as secondary variables.
Results: Lumiracoxib showed significant improvements in all primary and secondary variables compared
with placebo. Lumiracoxib 200 mg od and celecoxib 200 mg od achieved similar improvements in OA
pain intensity and functional status. Lumiracoxib 400 mg od demonstrated better efficacy for OA pain
intensity and patient’s global assessment of disease activity at weeks 2, 4, and 8 and similar efficacy at
week 13 compared with celecoxib 200 mg od. The incidence of adverse events (AEs), serious AEs, and
discontinuations due to AEs was similar in each group.
Conclusion: Lumiracoxib demonstrated significant improvement in OA pain intensity, patient’s global
assessment of disease activity, and the WOMAC pain subscale and total scores compared with placebo.
Lumiracoxib was well tolerated in this study, with overall tolerability similar to that of placebo and
celecoxib.
O
steoarthritis (OA) is a highly prevalent, chronic
condition associated with a considerable burden for
patients due to joint pain, stiffness, and inability to
perform normal daily activities. As a result, this condition has
a significant negative impact on quality of life.1
Non-steroidal anti-inflammatory drugs (NSAIDs) are well
established as first line treatment for chronic moderate-
severe pain in OA, providing effective relief of symptoms in
most patients.2–4 Traditional NSAIDs control the pain and
inflammation associated with OA by reducing prostaglandin
synthesis—a direct consequence of inhibitory effects on both
isoforms of the cyclo-oxygenase (COX) enzymes (COX-1 and
COX-2). This non-selective mechanism of action is largely
responsible for the development of symptomatic ulcers and
potentially serious gastrointestinal (GI) side effects.5 The
incidence of symptomatic ulcers and ulcer complications
associated with traditional NSAIDs was reported to be
between 2 and 4% a year in 1988,6 and the management of
gastropathy associated with traditional NSAID use is esti-
mated to more than double the costs associated with the
original treatment.7 The concomitant use of gastroprotective
agents with traditional NSAIDs has been reported as one
possible approach to managing NSAID related gastropathy.8
The GI side effects are due to reduced synthesis of prosta-
glandins, which have a cytoprotective role in the GI tract,
when COX-1 is inhibited by traditional NSAID treatment.9 10
Lumiracoxib is a new COX-2 selective inhibitor developed
for the treatment of OA, rheumatoid arthritis (RA), and acute
pain. It has demonstrated selectivity for COX-2 in vitro and in
vivo11 and in human studies,12 with selectivity maintained at
doses up to 1200 mg.13 The structure of lumiracoxib
distinguishes it from other COX-2 selective inhibitors,14
which may explain its preferential distribution into inflamed
tissue in animal models (an effect not observed with other
COX-2 selective inhibitors),15 16 and the sustained high
concentrations of lumiracoxib seen in synovial fluid com-
pared with plasma in patients with RA.17 Clinical studies
show that lumiracoxib is characterised by rapid absorption
(Tmax 2–3 hours), a short plasma half life (3–6 hours),
18 and
good oral bioavailability.19 In patients with OA, lumiracoxib
demonstrates dose proportional pharmacokinetics.20 Once
daily lumiracoxib provides relief from the pain, stiffness, and
impaired physical function of OA with efficacy better than
placebo and similar to diclofenac.21–23 Furthermore, lumira-
coxib is associated with a GI tolerability profile better than
ibuprofen and similar to celecoxib in patients with OA or
RA.24 25
This study aimed at determining the efficacy of two doses
of lumiracoxib (200 and 400 mg once daily (od)) in relieving
pain and improving functional status in patients with
primary knee OA, compared with placebo and celecoxib
200 mg od. The safety and tolerability profiles of all
treatment groups were also assessed.
Abbreviations: AE, adverse event; COX, cyclo-oxygenase; DPDA,
difficulty in performing daily activities; ECG, electrocardiogram; GI,
gastrointestinal; ITT, intention to treat; NOS, not otherwise specified;
NSAID, non-steroidal anti-inflammatory drug; OA, osteoarthritis; od,
once daily; RA, rheumatoid arthritis; SAE, serious adverse event; VAS,
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PATIENTS AND METHODS
This 13 week international, multicentre, randomised, double
blind, double dummy, placebo controlled, active comparator
study, was performed in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki (and
subsequent amendments).
Patients and study design
Men and women aged >18 years with a confirmed diagnosis
of primary OA of the knee, according to the American
College of Rheumatology criteria,26 were recruited after
giving written, informed consent. Patients at risk of
pregnancy or those who had secondary OA, other connective
tissue diseases, or significant medical problems, were
excluded.
People meeting the initial inclusion criteria underwent a
3–7 day washout period, during which NSAID treatment was
not permitted. At the end of the washout period, patients
with pain intensity in the affected knee measuring >40 mm
on a 100 mm visual analogue scale (VAS) (most pain) in the
past 24 hours were deemed eligible for entry into the
treatment phase of the study. To best reflect the ‘‘real life’’
clinical situation, no increase/worsening in OA symptoms
(flare) was required for study entry.
Table 1 Patient demographics and baseline disease characteristics
Lumiracoxib Lumiracoxib Celecoxib
Placebo200 mg od 400 mg od 200 mg od
(n = 487) (n = 491) (n = 481) (n = 243)
Age (years), mean (SD) {range} 64.1 (10.7) {20–93} 64.3 (10.4 {20–92} 64.1 (10.4 {30–91} 64.6 (9.9 {38–89}
Sex, No (%)
Male 148 (30.4) 160 (32.6) 148 (30.8) 80 (32.9)
Female 339 (69.6) 331 (67.4) 333 (69.2) 163 (67.1)
White, No (%) 482 (99.0) 485 (98.8) 475 (98.8) 242 (99.6)
Body mass index (kg/m2), mean (SD) {range} 29.5 (5.8) {17.1–62.1} 29.9 (5.8) {16.0–56.6} 30.0 (5.7) {18.4–63.6} 29.6 (5.4) {16.8–46.1}
OA disease duration (years), median 4.2 5.2 5.3 4.3
OA pain intensity in target knee (mm) 65.5 (14.9) 65.1 (14.1) 65.1 (14.2) 65.7 (13.3)
Patient’s global assessment of disease activity (mm) 62.9 (17.4) 62.6 (17.6) 63.6 (18.0) 63.2 (16.5)
Physician’s global assessment of disease activity (mm) 58.6 (14.1) 58.2 (14.2) 59.2 (15.0) 59.8 (14.3)
WOMAC total score 49.0 (14.9) 48.1 (15.0) 48.7 (15.4) 49.2 (14.0)
WOMAC pain subscale score 10.1 (3.4) 10.0 (3.3) 10.1 (3.3) 10.3 (3.0)
WOMAC DPDA subscale score 34.6 (11.2) 33.9 (11.4) 34.4 (11.7) 34.6 (10.4)
WOMAC stiffness subscale score 4.3 (1.7) 4.2 (1.7) 4.2 (1.7) 4.3 (1.7)
Results are given as mean (SD) unless stated otherwise.
DPDA, difficulty in performing daily activities; OA, osteoarthritis; od, once daily; SD, standard deviation; WOMAC, Western Ontario and McMaster Universities
Osteoarthritis Index.
Figure 1 Patient flow diagram. *Other includes protocol violation, withdrawal of consent, and condition no longer requiring the study drug.
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Patients were randomised to 13 weeks’ once daily treat-
ment with lumiracoxib 200 mg, lumiracoxib 400 mg, cele-
coxib 200 mg, or placebo. Celecoxib was administered at
200 mg od according to its label specifications. Blinding was
maintained by a double dummy technique. All drugs were
taken in the morning at least 1 hour before or after a meal,
the first dose being taken at the clinic on day 0 (baseline).
After this, patients returned to the clinic for assessment at
weeks 2, 4, 8, and 13.
Patients were permitted to take paracetamol ((2 g/day),
supplied by the investigator, as a rescue drug throughout the
trial; however, they were asked to refrain from using the
rescue drug from midnight before each clinic visit. NSAIDs
were not permitted during the course of the study, with the
exception of low dose aspirin ((325 mg/day) for a cardio-
vascular indication.
Prespecified criteria for discontinuation due to notable
changes in laboratory measures were established.
Outcome measures
The following primary efficacy variables were evaluated at
the end of the study (week 13):
N OA pain intensity (VAS mm) in the target knee (most pain
in the previous 24 hours)
N Patient’s global assessment of disease activity (VAS mm)
N Patient’s functional status (pain subscale and total score of
the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) LK3.1 questionnaire).27
OA pain intensity in the target knee, patient’s and
physician’s global assessment of disease activity, and
WOMAC (total and all three subscale scores: pain, difficulty
in performing daily activities (DPDA), and stiffness) were
analysed by visit as secondary variables.
Safety was assessed through recording the frequency of
adverse events (AEs) and serious adverse events (SAEs) at
each clinic visit. Physical examinations were performed at
baseline and at the study end, vital signs were assessed
at each clinic visit, and standard laboratory tests were
performed at weeks 2, 4, and 13. Electrocardiogram (ECG)
measurements, analysed centrally, were conducted at screen-
ing, week 4, and week 13. A subgroup of patients, whose
ECGs after baseline were recorded 1–4 hours after the
morning dose of study drug to coincide with the maximum
plasma concentration (Cmax) of lumiracoxib,
18 were included
into ‘‘peak time’’ analyses of ECG parameters.
Compliance with study treatment was monitored by pill
counting, and rescue drug use was assessed at each study
visit.
Statistical analyses
A minimum sample size of 432 patients in each active
treatment group and 216 in the placebo group was specified
in the study protocol—that is, a total of 1512 patients. Using
a two group t test with a 0.025 one tailed significance level,
this sample size would have 99% power to reject the null
hypothesis of no treatment difference over placebo, assuming
a difference of 11 mm in favour of lumiracoxib, a withdrawal
rate of 15%, and a common standard deviation of 25 mm.
A high power was set to enable tests of non-inferiority
or superiority of lumiracoxib to celecoxib. To this end,
Figure 2 Osteoarthritis pain intensity (VAS mm) in the target knee at
weeks 2, 4, 8, and 13 with lumiracoxib (200 mg and 400 mg od),
celecoxib (200 mg od), and placebo. Values are least square means,
except for baseline, which are means. ***p(0.001 all active treatment
groups v placebo; p,0.05 lumiracoxib 400 mg od v celecoxib
200 mg od; `p,0.05 lumiracoxib 400 mg od v lumiracoxib
200 mg od.
Table 2 Change from baseline in OA pain intensity in the target joint, and patient’s and physician’s global assessments of
disease activity at weeks 2 and 13
OA pain intensity in the target joint
Patient’s global assessment of
disease activity
Physician’s global assessment of
disease activity
Week 2 Week 13 Week 2 Week 13 Week 2 Week 13
Lumiracoxib 200 mg od (n = 487) 219.2 (21.7) 226.0 (26.3) 214.9 (22.4) 223.2 (26.9) 214.6 (18.4) 223.0 (22.4)
Lumiracoxib 400 mg od (n = 491) 220.2 (21.0) 227.4 (24.5) 216.4 (20.8) 224.1 (25.0) 214.3 (17.0) 223.6 (21.4)
Celecoxib 200 mg od (n = 481) 217.5 (20.5) 225.2 (24.7) 214.3 (20.6) 222.4 (25.7) 214.0 (16.9) 222.4 (22.0)
Placebo (n = 243) 29.1 (19.3) 219.8 (26.1) 27.9 (19.2) 215.7 (26.1) 28.3 (17.3) 218.0 (24.3)
Results are shown as mean (SD).
Figure 3 Patient’s global assessment of disease activity (VAS mm) at
weeks 2, 4, 8, and 13 with lumiracoxib (200 mg and 400 mg od),
celecoxib (200 mg od), and placebo. Values are least square means,
except for baseline, which are means. ***p(0.001 all active treatment
groups v placebo; p,0.05 lumiracoxib 400 mg od v celecoxib
200 mg od.
Lumiracoxib in the treatment of OA of the knee 1421
www.annrheumdis.com
 on 14 July 2009 ard.bmj.comDownloaded from 
non-inferiority margins of 5 mm for OA pain and patient’s
global assessment, and of 0.6 points for the pain subscale of
the WOMAC questionnaire were predefined.
Patients were randomised in a ratio of 2:2:2:1 to 13 weeks’
once daily treatment with lumiracoxib 200 mg, lumiracoxib
400 mg, celecoxib 200 mg, or placebo.
Each primary efficacy variable was analysed, using analysis
of covariance, with baseline values as the covariate, with
treatment group and study centre as the independent
variables. Pairwise comparisons between treatments were
performed using least square means obtained from the
model. Data were analysed by visit at a secondary level using
the same model.
All safety and efficacy evaluations were performed using
the intention to treat (ITT) population. The safety and ITT
populations were identical and included all patients rando-
mised to treatment who had been exposed to the study drug.
Conventional last observation carried forward methodology
was used when data were missing.
In addition to the analysis of AE and SAE incidence, the
incidence of prespecified AEs was compared in treated and
placebo groups using medical terms as coded by a standard
medical dictionary.
N Prespecified GI AEs and ulcers: abdominal pain not
otherwise specified (NOS), abdominal pain lower, abdom-
inal pain upper, abdominal pain aggravated, constipation,
constipation aggravated, diarrhoea NOS, diarrhoea aggra-
vated, nausea, nausea aggravated, vomiting NOS, vomiting
aggravated, dyspepsia, dyspepsia aggravated, dysphagia,
dysphagia aggravated, loose stools, oesophageal ulcer, peptic
ulcer, peptic ulcer aggravated, gastric ulcer, duodenal ulcer,
duodenal ulcer aggravated, gastroduodenal ulcer, GI ulcer,
pyloric ulcer
N Peripheral oedema AEs: oedema peripheral, oedema lower
limb, oedema NOS, oedema upper limb
N Chest pain AEs: chest pain not elsewhere classified.
Occurrence of prespecified AEs was summarised and
analysed using a logistic regression model, including country
and treatment group as variables.
RESULTS
Patient characteristics
The ITT population comprised 1702 patients, randomised to
receive lumiracoxib 200 mg od (n=487), lumiracoxib
400 mg od (n=491), celecoxib 200 mg od (n=481) or
placebo (n=243). The study group was predominantly
female (68.5%) with a mean age of approximately 64 years.
There were no significant differences in patient demographics
or baseline disease characteristics between the treatment
groups (table 1).
A similar number of patients discontinued the study
prematurely in each active treatment group (fig 1). Most
discontinuations resulted from AEs; however, the proportion
of patients who withdrew for this reason was similar across
the four treatment groups. Overall, compliance with the
treatment regimens was good, with more than 90% of
patients judged to be compliant across the four treatment
groups. Proportionately twice as many patients discontinued
owing to a lack of efficacy in the placebo group as in the
active treatment groups (fig 1).
Efficacy
Primary variables
All active treatments were statistically significantly better
than placebo for each of the primary variables at 13 weeks.
For OA pain intensity (VAS mm) in the target knee at week
13, the estimated least square mean differences from placebo
in favour of active treatment were 6.33 mm (p,0.001) in the
lumiracoxib 200 mg od group, 7.94 mm (p,0.001) in the
lumiracoxib 400 mg od group, and 5.75 mm (p=0.001) in
the celecoxib 200 mg od group (fig 2). The mean change from
baseline in OA pain intensity at week 13 was similar for all
active treatments (226.0 mm for lumiracoxib 200 mg od,
227.4 mm for lumiracoxib 400 mg od, and 225.2 mm for
celecoxib 200 mg od) compared with 219.8 mm for placebo
(table 2), and the non-inferiority of lumiracoxib 200 and
400 mg od to celecoxib 200 mg od was demonstrated.
Significant improvement in patient’s global assessment of
disease activity was seen in all active treatment groups at
week 13 compared with placebo (all p,0.001 v placebo; fig 3,
table 2). All active treatments were similar and non-
inferiority of lumiracoxib 200 and 400 mg od to celecoxib
200 mg od was demonstrated.
The WOMAC pain subscale and total scores at week 13
were significantly better with lumiracoxib and celecoxib than
with placebo (all p,0.01 v placebo for the pain subscale and
all p,0.001 for the total score). Figure 4 and table 3 show the
mean changes from baseline.
Secondary variables
Significant improvements were seen in OA pain intensity
(VAS mm) in the target knee from week 2 onwards in all
active treatment groups compared with placebo (table 2,
fig 2). The reduction in pain intensity with lumiracoxib
200 mg od was of similar magnitude to that of celecoxib
200 mg od at all times. At weeks 2, 4, and 8, lumiracoxib
400 mg od provided significantly greater reductions in OA
pain intensity in the target knee than celecoxib 200 mg od.
The patient’s global assessment of disease activity (VAS
mm) was significantly improved from week 2 onwards in all
active treatment groups compared with placebo (table 2,
Figure 4 Mean (SEM) change from baseline in WOMAC pain subscale
(A) and total (B) scores at week 13 with lumiracoxib (200 mg and
400 mg od), celecoxib (200 mg od), and placebo. Statistical analyses
performed using least square means. **p,0.01 v placebo; ***p,0.001
v placebo.
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fig 3). In the lumiracoxib 400 mg od group, the reduction in
the mean score was significantly greater than in the celecoxib
200 mg od group at weeks 2, 4, and 8 (fig 3). In addition, all
active treatment groups were significantly more efficacious
than placebo at weeks 2, 4, 8, and 13 according to the
physician’s global assessment of disease activity (table 2).
Significant improvements were seen in WOMAC total and
all three subscale scores for all active treatment groups
compared with placebo at week 2 (all p,0.01 v placebo;
table 3). At week 13, all active treatments were associated
with significant improvements according to the DPDA and
stiffness subscales (all p,0.01 v placebo; table 3).
The mean number of rescue drug tablets consumed was
significantly greater in the placebo group (0.8 tablets/day)
than in any active treatment group throughout the study (0.5
tablets/day for both lumiracoxib groups and 0.6 tablets/day
for celecoxib 200 mg od; all p,0.05 v placebo). Between-
treatment analyses showed that at week 4, the number of
rescue drug tablets taken was significantly higher in the
celecoxib 200 mg od group than in the lumiracoxib 400 mg
od group; no other between-treatment differences were seen
(data not shown).
Safety
Lumiracoxib was well tolerated. There were no deaths during
the study and the incidence of SAEs was similar in all active
treatment groups and the placebo group (2.5% of patients
receiving lumiracoxib 200 mg od, 2.9% receiving lumiracoxib
400 mg od, 2.9% receiving celecoxib 200 mg od, and 3.3%
receiving placebo; table 4). The proportion of patients
reporting at least one AE was 57.5% and 58.7% in the
lumiracoxib 200 mg od and 400 mg od groups, respectively,
compared with 51.0% for the placebo group and 53.2% for the
celecoxib 200 mg od group. AEs led to discontinuation from
the study in a similar proportion of patients in each
treatment group. In all treatment groups the most common
AEs leading to discontinuation were those affecting the GI
system: 18 (3.7%) patients in the lumiracoxib 200 mg od
group, 22 (4.5%) patients in the lumiracoxib 400 mg od
group, 19 (4.0%) patients in the celecoxib 200 mg od group,
and 6 (2.5%) patients in the placebo group (table 4). In a post
hoc analysis, no statistically significant differences were
detected in discontinuation rates for GI AEs between any
active treatments compared with placebo.
The majority of AEs were mild or moderately severe. The
incidence and nature of AEs were similar in both lumiracoxib
groups and the celecoxib group; overall, nasopharyngitis,
headache, and upper abdominal pain, were the most
commonly reported AEs in all treatment groups (table 5).
Multiple regression analyses of the incidence of prespeci-
fied AEs showed no significant differences between lumira-
coxib and celecoxib (table 5). The proportion of patients
reporting prespecified GI events was similar in each active
treatment group. The incidence of prespecified peripheral
oedema and chest pain was low, and no clinically relevant
pattern was seen between treatment groups.
Clinically relevant laboratory abnormalities were uncom-
mon in all treatment groups; however, four patients were
withdrawn from the study because of abnormal values. As
required by study protocol, one patient in the lumiracoxib
400 mg od group discontinued because of a raised creatinine
level (.26 the upper limit of normal). In total, nine patients
had increases in liver function parameters (alanine amino-
transferase/aspartate aminotransferase) .36 the upper limit
of normal (two patients in the lumiracoxib 200 mg od group;
three patients in the lumiracoxib 400 mg od group; four
patients in the celecoxib 200 mg od group). Of these nine
patients, three were withdrawn from the study (one patient
in each of the lumiracoxib 200 mg od, lumiracoxib 400 mg
od, and celecoxib 200 mg od groups). All cases of raised liver
function parameters resolved either while receiving the study
drug or after treatment had stopped and none were
accompanied by clinical symptoms.
ECG analyses showed that lumiracoxib was not associated
with QT interval prolongation or any form of arrhythmia.
There was no evidence of drug or dose related changes in
ECG recordings or increase in qualitative ECG abnormalities
in any treatment group.
DISCUSSION
The results of this large, randomised, double blind, placebo
controlled, active comparator study demonstrate the clinical
efficacy and tolerability of lumiracoxib, a new COX-2
selective inhibitor, at doses of 200 or 400 mg od, in patients
with OA of the knee. After 13 weeks of treatment, patients
Table 3 Change from baseline in WOMAC total and subscale scores at weeks 2 and 13





Week 2 Week 13 Week 2 Week 13 Week 2 Week 13 Week 2 Week 13
Lumiracoxib 200 mg od (n =487) 210.6 (13.2) 214.1 (16.8) 22.6 (3.3) 23.2 (4.3) 26.9 (9.6) 29.8 (12.1) 21.0 (1.7) 21.2 (1.8)
Lumiracoxib 400 mg od (n =491) 29.8 (13.9) 214.1 (16.9) 22.6 (3.4) 23.2 (3.8) 26.4 (10.3) 29.7 (12.6) 20.9 (1.6) 21.2 (1.8)
Celecoxib 200 mg od (n = 481) 28.6 (13.1) 213.4 (15.8) 22.4 (3.1) 23.1 (3.8) 25.5 (9.9) 29.2 (11.6) 20.8 (1.6) 21.2 (1.7)
Placebo (n =243) 24.3 (12.4) 29.4 (16.1) 21.4 (3.3) 22.4 (3.8) 22.4 (8.8) 26.2 (11.8) 20.5 (1.5) 20.9 (1.6)
DPDA, difficulty in performing daily activities; od, once daily; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.







200 mg od Placebo
(n = 487) (n = 491) (n = 481) (n = 243)
Patients with SAEs 12 (2.5) 14 (2.9) 14 (2.9) 8 (3.3)
Patients with AEs 280 (57.5) 288 (58.7) 256 (53.2) 124 (51.0)
Discontinuations due to AEs 42 (8.6) 43 (8.8) 47 (9.8) 21 (8.6)
Discontinuations due to GI AEs 18 (3.7) 22 (4.5) 19 (4.0) 6 (2.5)
Results are shown as No (%).
AE, adverse event; GI, gastrointestinal; od, once daily; SAE, serious adverse event.
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who had received lumiracoxib 200 and 400 mg od had
significantly less OA pain intensity in the target knee, and
better patient’s global assessment of disease activity and
patient’s functional status than the placebo group.
Analyses of OA pain intensity in the target knee and
patient’s global assessment of disease activity by clinic visit
(secondary variables) showed that both doses of lumiracoxib
provided statistically significant improvements over placebo
from the first clinic visit after the start of treatment (week 2),
an effect sustained throughout the study. The magnitude of
improvement was similar for lumiracoxib 200 mg od and
celecoxib 200 mg od at all times. Lumiracoxib 400 mg od was
significantly more effective than celecoxib 200 mg od at
weeks 2, 4, and 8, but no significant differences were seen by
the study end (week 13). For the other secondary efficacy
variables, physician’s global assessment of disease activity,
and WOMAC DPDA and stiffness subscales, both lumiracoxib
groups and the celecoxib group were significantly better than
placebo throughout the study.
Celecoxib has been shown to provide sustained analgesic
effects and improvements in physical function in patients
with OA, with efficacy better than placebo and similar to that
of the traditional NSAIDs, naproxen and diclofenac.28 29
Celecoxib was therefore chosen as a reference treatment for
this study, and was used at the recommended dose for the
treatment of OA.30 Thus, it is notable that in this study
lumiracoxib 200 mg od was found to be similar to celecoxib
in all clinical efficacy measures examined.
This study recruited patients without OA flare to replicate
the ‘‘real life’’ clinical situation for patients with OA. In
previously reported celecoxib studies in OA, a flare design
was used, whereby patients were required to demonstrate
a worsening in OA symptoms during an NSAID washout
period between screening and baseline.28 31 In both these
studies a marked placebo effect was seen in the mean change
from baseline in OA pain intensity (VAS mm), and celecoxib
was associated with mean changes from baseline of up to
230.0 mm and differences in comparison with placebo of
up to 215.0 mm after 2 weeks of treatment.28 31 In our
study the lack of a requirement for OA flare would be
expected to provide an overall less dramatic treatment effect
and, consequently, a smaller difference compared with
placebo.
In addition, it has recently been suggested that the concept
of a minimal clinically perceptible difference is applicable to
the WOMAC DPDA subscale, whereby the minimal difference
perceived by 75% of patients (MDP75) is considered to
represent a clinically meaningful difference. In a study
sample of 1354 patients with hip and knee OA, the MDP75
for the WOMAC DPDA subscale was found to be 5.2.32 It is
notable that in the study reported here, mean changes in
WOMAC DPDA subscale scores were .6 for both doses of
lumiracoxib at week 2, rising to .9 at week 13.
Celecoxib and rofecoxib are associated with a lower
incidence of ulcers and GI events than traditional non-
selective NSAIDs.33–35 Although the results of the Celecoxib
Outcomes Study (CLASS) were not positive for celecoxib
compared with traditional non-selective NSAIDs for ulcer
related complications at 12 months,36 37 a recent systematic
review of a wide range of celecoxib studies found that it does
offer significantly improved GI safety and tolerability
(including ulcers and serious upper GI events) compared
with traditional NSAIDs.38 In this study both doses of
lumiracoxib and celecoxib were associated with a similar
incidence of AEs, including GI disorders, suggesting no dose
relationship. In addition, the number of patients who
withdrew from the study because of AEs or GI-specific AEs
was similar across all active treatment groups. Furthermore,
lumiracoxib was not associated with an increase in overall
renal AEs or associated symptoms of oedema compared with
placebo, and did not result in QT interval prolongation or any
form of arrhythmia.
The efficacy and tolerability of lumiracoxib seen in this
study confirm findings of earlier studies in patients with
OA. In a 4 week study of 583 patients with primary OA of
the hip and knee, lumiracoxib demonstrated efficacy
comparable with the traditional NSAID, diclofenac, for
pain relief, improved functional status, and response to
treatment.21 In a 13 week study comparing the GI effects
of lumiracoxib with ibuprofen and celecoxib in 1042
patients with primary OA of the hip, knee, hand, or spine,
lumiracoxib was associated with significantly fewer gastro-
duodenal ulcers than ibuprofen. In addition, it was notable
that lumiracoxib and celecoxib demonstrated a similar GI
tolerability profile.24 Lumiracoxib resulted in significantly
lower rates of gastroduodenal ulceration than ibuprofen in a
separate study of 893 patients with RA; the incidence of
gastroduodenal ulcers was also similar for lumiracoxib and
celecoxib in this study.25 Similarly, in healthy volunteers,
lumiracoxib was associated with a reduced incidence of
gastroduodenal erosions compared with the traditional
NSAID, naproxen.12 39
In summary, our study shows that lumiracoxib at a dose of
200 or 400 mg od provides sustained relief from the painful







200 mg od Placebo
(n = 487) (n = 491) (n = 481) (n = 243)
Most frequently reported AEs
Nasopharyngitis 34 (7.0) 28 (5.7) 23 (4.8) 12 (4.9)
Headache 19 (3.9) 29 (5.9) 27 (5.6) 9 (3.7)
Abdominal pain upper 23 (4.7) 25 (5.1) 25 (5.2) 6 (2.5)
Arthralgia 15 (3.1) 11 (2.2) 14 (2.9) 11 (4.5)
Dyspepsia 19 (3.9) 21 (4.3) 17 (3.5) 9 (3.7)
Diarrhoea 13 (2.7) 18 (3.7) 11 (2.3) 2 (0.8)
Back pain 8 (1.6) 14 (2.9) 17 (3.5) 8 (3.3)
Hypertension NOS 8 (1.6) 17 (3.5) 12 (2.5) 2 (0.8)
Influenza 11 (2.3) 16 (3.3) 11 (2.3) 7 (2.9)
Prespecified AEs 94 (19.3) 101 (20.6) 77 (16.0) 30 (12.3)
GI events 85 (17.5) 96 (19.6) 72 (15.0) 25 (10.3)
Peripheral oedema 6 (1.2) 4 (0.8) 6 (1.2) 4 (1.6)
Chest pain 3 (0.6) 4 (0.8) 2 (0.4) 1 (0.4)
Results are shown as No (%).
AE, adverse event; GI, gastrointestinal; NOS, not otherwise specified; od, once daily.
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symptoms of OA of the knee and improves functional status
with significantly better efficacy than placebo. In addition,
lumiracoxib was found to be as effective and well tolerated as
the recommended dose of the established COX-2 selective
inhibitor, celecoxib.
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